LUPUS ANTICOAGULANT AND CARDIAC MANIFESTATIONS IN SYSTEMIC LUPUS-ERYTHEMATOSUS

被引:45
作者
JOUHIKAINEN, T
POHJOLASINTONEN, S
STEPHANSSON, E
机构
[1] UNIV HELSINKI, CENT HOSP, DEPT MED 1, SF-00100 HELSINKI 10, FINLAND
[2] KAROLINSKA HOSP, DEPT DERMATOL, S-10401 STOCKHOLM 60, SWEDEN
关键词
ANTIPHOSPHOLIPID ANTIBODIES; HEART FAILURE; LIBMAN-SACKS ENDOCARDITIS; MYOCARDIAL INFARCTION; THROMBOSIS;
D O I
10.1177/096120339400300307
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The occurrence of cardiac manifestations and their relationship with the lupus anticoagulant (LA) in SLE was studied iii 74 patients who were followed up for 22 years (median), of which 16 years were after the initial LA testing. Pericarditis was the most common cardiac event occuring in 16 (22%) patients but it did not correlate with LA. Valvular heart disease, coronary artery disease, left ventricular failure and/or cor pulmonale were observed in 16 (22%) patients. Taken together, their occurrence was associated with a history of leg ulcers (odds 3.8, P = 0.028) but not with LA or other common clinical manifestations of the antiphospholipid syndrome. Valvular heart disease in five patients was significantly associated with LA (P = 0.05). Cor pulmonale due to chronic pulmonary embolism was present in two patients with LA. Myocardial infarctions in five patients occurred late in the course of disease but in relatively young patients (mean 43 years). Fatal myocardial infarction in the absence of atherosclerosis in two LA-positive patients supports a pathogenetic role for LA in these cases. In conclusion, of the various cardiac complications in SLE, valvular heart disease and cor pulmonale appear to be connected with the antiphospholipid syndrome. Both conditions should be actively sought in patients with LA to decrease possible adverse events (arterial emboli and right ventricular failure) affecting the patients' prognosis.
引用
收藏
页码:167 / 172
页数:6
相关论文
共 46 条
[1]   ANTIPHOSPHOLIPID ANTIBODIES AND THE ANTIPHOSPHOLIPID SYNDROME IN SYSTEMIC LUPUS-ERYTHEMATOSUS - A PROSPECTIVE ANALYSIS OF 500 CONSECUTIVE PATIENTS [J].
ALARCONSEGOVIA, D ;
DELEZE, M ;
ORIA, CV ;
SANCHEZGUERRERO, J ;
GOMEZPACHECO, L ;
CABIEDES, J ;
FERNANDEZ, L ;
DELEON, SP .
MEDICINE, 1989, 68 (06) :353-365
[2]   SKIN-LESIONS ASSOCIATED WITH CIRCULATING LUPUS ANTICOAGULANT [J].
ALEGRE, VA ;
GASTINEAU, DA ;
WINKELMANN, RK .
BRITISH JOURNAL OF DERMATOLOGY, 1989, 120 (03) :419-429
[3]   THE LUPUS ANTICOAGULANT, PULMONARY THROMBOEMBOLISM, AND FATAL PULMONARY-HYPERTENSION [J].
ANDERSON, NE ;
ALI, MR .
ANNALS OF THE RHEUMATIC DISEASES, 1984, 43 (05) :760-763
[4]  
ASHERSON RA, 1993, J INVEST DERMATOL, V100, pS21
[5]   THE PRIMARY ANTIPHOSPHOLIPID SYNDROME - MAJOR CLINICAL AND SEROLOGICAL FEATURES [J].
ASHERSON, RA ;
KHAMASHTA, MA ;
ORDIROS, J ;
DERKSEN, RHWM ;
MACHIN, SJ ;
BARQUINERO, J ;
OUTT, HH ;
HARRIS, EN ;
VILARDELLTORRES, M ;
HUGHES, GRV .
MEDICINE, 1989, 68 (06) :366-374
[6]  
ASHERSON RA, 1989, Q J MED, V73, P1103
[7]  
ASHERSON RA, 1991, PHOSPHOLIPID BINDING
[8]   THROMBOSIS IN SYSTEMIC LUPUS-ERYTHEMATOSUS - STRIKING ASSOCIATION WITH THE PRESENCE OF CIRCULATING LUPUS ANTICOAGULANT [J].
BOEY, ML ;
COLACO, CB ;
GHARAVI, AE ;
ELKON, KB ;
LOIZOU, S ;
HUGHES, GRV .
BMJ-BRITISH MEDICAL JOURNAL, 1983, 287 (6398) :1021-1023
[9]   AORTIC-INSUFFICIENCY AND MITRAL REGURGITATION IN PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS AND THE ANTIPHOSPHOLIPID SYNDROME [J].
CHARTASH, EK ;
LANS, DM ;
PAGET, SA ;
QAMAR, T ;
LOCKSHIN, MD .
AMERICAN JOURNAL OF MEDICINE, 1989, 86 (04) :407-412
[10]   CRITERIA FOR CLASSIFICATION OF SLE [J].
DAVIS, P ;
ATKINS, B ;
JOSSE, RG ;
HUGHES, GRV .
BRITISH MEDICAL JOURNAL, 1973, 3 (5871) :88-89